Brief: Orexo Raises FY OPEX Guidance To Reflect US Launches Of Deprexis And Vorvida

Orexo AB

02/07/2020 07:10

July 2 (Reuters) - Orexo AB  ORX.ST :
    * OREXO LAUNCHES DEPREXIS® AND VORVIDA® IN THE US AND
PROVIDES
UPDATED FINANCIAL GUIDANCE
    * PRELIMINARY ESTIMATED SALES POTENTIAL OF USD 420-650
MILLION FOR
DTX PORTFOLIO FIVE YEARS POST LAUNCH
    * NEW OPEX GUIDANCE FOR 2020 IS INCREASED TO SEK 750-800
MILLION
FROM SEK 550-600 MILLION REFLECTING INVESTMENTS RELATED TO
ACCELERATED COMMERCIALIZATION AND ESTABLISHMENT OF DTX BUSINESS
    * INITIAL REVENUES FROM DIGITAL THERAPEUTICS ARE EXPECTED IN
Q3
2020 AND TOTAL NET REVENUES IN 2020 FROM DIGITAL THERAPIES ARE
DEPENDENT ON PACE OREXO CAN SECURE PRODUCT REIMBURSEMENT
    * OREXO WILL LEVERAGE COMPANY'S STRONG FINANCIAL POSITION TO
INVEST IN EARLY LAUNCH OF DIGITAL THERAPIES DURING 2020
    * TO ENABLE ACCELERATED LAUNCH OF ALL THREE PRODUCTS
INVESTMENTS
WILL INCREASE AND OPEX FOR FY 2020 IS EXPECTED TO BE IN RANGE OF
SEK 750-800 MILLION, FROM SEK 550-600 MILLION

Source text for Eikon:  ID:nWkr6cYKC2 
Further company coverage:  ORX.ST 

 (Gdansk Newsroom)
 ((gdansk.newsroom@thomsonreuters.com; +48 58 778 51 10;))